Skip to main content

Day: October 5, 2025

Predictive Discovery & Robex Announce Merger of Equals

Pathway to Becoming One of West Africa’s Leading Gold Producers TRANSACTION HIGHLIGHTSCreates West Africa’s next mid-tier gold producer by combining two of the continent’s largest, lowest-cost, and most advanced projects. Combined production expected to exceed 400kozpa Au1 by 2029. Combined Mineral Resources of approximately 9.5Moz Au2 inclusive of Ore Reserves3 of approximately 4.5Moz Au4 with significant exploration upside potential. Transaction will drive economic growth in Guinea, strengthen local labour force, enhance critical infrastructure and services, and build lasting local partnerships. Development funding for PDI’s Bankan project (the “Bankan Project”) will be significantly de-risked by leveraging cash flows from Robex’s Kiniero project (the “Kiniero Project”) and the ongoing...

Continue reading

Weebit Nano tapes out embedded ReRAM test chips at onsemi production fab

Innovative Non-Volatile Memory (NVM) technology to be available in 65nm BCD process HOD HASHARON, Israel, Oct. 05, 2025 (GLOBE NEWSWIRE) — Weebit Nano Limited (ASX:WBT) (Weebit), a leading developer and licensor of advanced memory technologies for the global semiconductor industry, has successfully taped-out (released to manufacturing) test chips featuring its embedded Resistive Random-Access Memory (ReRAM) module at onsemi’s 300mm production fab in East Fishkill, NY. The chips are being developed in onsemi’s Treo platform, which is a 65nm Bipolar-CMOS-DMOS (BCD) process. onsemi (Nasdaq: ON) is a U.S. based company that delivers intelligent power and sensing solutions for the automotive, industrial and AI data center markets. This tape-out represents a key milestone towards enabling Weebit ReRAM IP on onsemi’s Treo™ platform....

Continue reading

Firefly Aerospace Announces Strategic Acquisition of SciTec to Advance National Security Capabilities

Addition of SciTec’s full-stack software and big data processing capabilities expands Firefly’s responsive launch, land, and orbit mission services for space and defense customersCEDAR PARK, Texas, Oct. 05, 2025 (GLOBE NEWSWIRE) — Firefly Aerospace (Nasdaq: FLY), a market leading space and defense technology company, has entered into a definitive agreement to acquire SciTec, Inc., a leader in advanced national security technologies, for approximately $855 million through a combination of $300 million in cash and $555 million in Firefly shares issued to SciTec owners at a price of $50 per share. “The acquisition of SciTec enhances our ability to support a growing number of defense missions and provides us with a significant operational advantage,” said Jason Kim, CEO of Firefly Aerospace. “SciTec’s mission-proven software and...

Continue reading

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects in both trials – – After 14 days of treatment in healthy volunteers, ARV-102 decreased lysosomal and neuroinflammatory microglial pathway biomarkers known to be elevated in Parkinson’s disease – NEW HAVEN, Conn., Oct. 05, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced positive pharmacokinetic, pharmacodynamic, and biomarker data from two Phase 1 clinical trials evaluating ARV-102, an oral, brain-penetrant investigational PROTAC degrader of leucine-rich repeat kinase 2 (LRRK2). Results were presented at...

Continue reading

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced scientific presentations at the UEGW Congress. “We are excited to share follow-up data out to six months from our Phase 1 study of SPY002, our potential best-in-class anti-TL1A agent in development for IBD. The data continue to show SPY002 is well tolerated, has a differentiated PK profile supporting quarterly or twice-yearly dosing, and suppresses free TL1A through 24 weeks,” said Josh Friedman, M.D., Ph.D., SVP of Clinical Development at Spyre. “Additionally, we are pleased to share new preclinical...

Continue reading

MOG Digitech (01942.HK) Makes Exclusive Strategic Investment in Luckyins Technology (Hong Kong), Collaborating to Shape New Insurtech Landscape

HONG KONG, Oct. 05, 2025 (GLOBE NEWSWIRE) — MOG Digitech Holdings Limited (01942.HK) announced the completion of a strategic investment in Luckyins Technology (HongKong) Co., Limited, an emerging force in Hong Kong’s insurtech sector. This move marks another significant step for MOG Digitech in driving the digital transformation of the insurance industry and advancing its ongoing strategic layout in Web3 insurance. Luckyins Technology (HongKong) Co., Limited is a tech enterprise focused on optimizing insurance business processes through AI technology, offering modular solutions that cover insurance sales, operations, finance, and after-sales management. Concurrently, the company also serves as a technical service provider utilizing blockchain technology to deliver digital payment solutions for the insurance industry. MOG...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.